Uncategorized

ORPHELIA announces the appointment of Dr. Caroline Lemarchand as Chief Pharmaceutical Development Officer

First-in-class immune checkpoint inhibitor to be presented at SITC

ORPHELIA announces that the CHMP has adopted a positive opinion for Ivozall®

Ivozall® is an essential medicine intended for the treatment of relapsed or refractory Acute Lymphoblastic Leukaemia in children

Baikowski® hereby confirms its acquisition of Mathym SAS, a company with which it commenced negotiations in July 2019

Two new projects supported by our Endowment Fund

The 18th of september 2019, the board of directors of our Endowment Fund Dominique & Tom Alberici decided to support “Douleurs sans Frontières” and “Anyma”, two projects in Madagascar.

Two new projects supported by our Foundation

The 18th of september 2019, the board of directors of the Foundation Dominique & Tom Alberici decided to support “Odynéo” and “Léthé Musicale”,

ORPHELIA announces Orphan Drug Designation for Kimozo®

Signature of a memorandum of understanding for the acquisition of Mathym SAS

Baikowski® has signed a memorandum of understanding for the acquisition, subject to the satisfaction of conditions precedent, of Mathym SAS, a company located at Champagne-au-Montd’Or in France.

Alizé Pharma 3

Alizé Pharma 3 raises €67 million ($75 million) in Series A from a strong international syndicate

ORPHELIA Pharma and DESITIN GmbH announce the launch of Kigabeq® in Germany

ORPHELIA Pharma announces today that it has entered into a collaboration agreement with the epilepsy specialist Desitin GmbH to distribute Kigabeq® in Germany.